Promising drug targets childhood eye muscle disease

NCT ID NCT07298928

Not yet recruiting Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called Telitacicept in 30 children with ocular myasthenia gravis, a condition that causes droopy eyelids and double vision. The drug aims to reduce relapses and the need for steroids. It is given as a weekly shot alongside standard care. The trial is open-label and early-stage, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telitacicept (a targeted B-cell biologic drug given as a shot)
What this could lead to: If it works, this could offer a new treatment option for children with ocular myasthenia gravis, reducing relapses and the need for steroids.
What could go wrong: This is a small, early-phase trial with no control group, so results may not be conclusive. The drug also carries risks like infection and is not yet approved for children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFECTIVENESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile myasthenia gravis myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFFECTIVENESS

Contacts and locations

Locations

Children's Hospital Affiliated to Shandong University

Jinan, Shandong, China
Shenzhen children's Hospital of China Medical University

Shenzhen, Guangdong, China
The Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.